International Stem Cell Corporation
2595 Jason Court
Oceanside
California
92056
United States
Tel: 760-940-6383
Fax: 760-940-6387
Website: http://www.internationalstemcell.com/
Email: info@IntlStemCell.com
217 articles about International Stem Cell Corporation
-
International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022
5/17/2022
International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, provided a business update and financial results for the three months ended March 31, 2022.
-
International Stem Cell Corporation Announces 2021 Fourth Quarter and Year-End Results
3/30/2022
International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2021.
-
International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease
6/30/2021
International Stem Cell Corporation announced today successful completion of its dose escalating phase 1 clinical trial.
-
OTC Markets Group Welcomes International Stem Cell Corporation to OTCQX
3/4/2019
OTC Markets Group Inc. announced International Stem Cell Corporation has qualified to trade on the OTCQX® Best Market.
-
International Stem Cell Corporation Announces Record Sales and Operating Results for the Three and Six-Months ended June 30, 2018
8/15/2018
Consolidated revenue for the six months ended June 30, 2018 was $5.7 million, an increase of 50% compared to the consolidated revenue of $3.8 million for the six months ended June 30, 2017.
-
International Stem Cell Corporation Expands Manufacturing Capabilities for Biomedical Products
7/10/2018
International Stem Cell Corporation announced today that Lifeline Cell Technology (LCT), has expanded its business and manufacturing capabilities to fulfill current and forecasted demand.
-
International Stem Cell Corporation Doses First Patient of the Third Cohort in Parkinson's Disease Clinical Trial
6/11/2018
International Stem Cell Corporation announced that the first patient of the third cohort of the clinical trial for Parkinson's disease was successfully transplanted with 70,000,000 ISC-hpNSC®.
-
International Stem Cell Corporation is Valued at $33M Market Value by Edison Investment Research
1/22/2018
The report features an analysis of ISCO’s financial data, along with an investment summary that showcases the company’s cell therapy for Parkinson’s disease and Traumatic Brain Injury as a key industry differentiator.
-
International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017
11/17/2017
Combined operating income for the nine months ended September 30, 2017 from our two wholly owned revenue-generating subsidiaries was $1.3 million, an increase of 30% compared to $1.0 million in the same period in 2016.
-
International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson's Disease Clinical Trial
11/13/2017
All patients in the first cohort are currently meeting the primary endpoint, which is safety.
-
International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted To Treat Liver Diseases
10/9/2017
-
International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted To Treat Liver Diseases
10/9/2017
-
International Stem Cell Corporation To Expand Its Revenue Generating Biomedical Businesses To Support Ongoing And Future Clinical Trials
9/26/2017
-
International Stem Cell Corporation To Move Forward With Traumatic Brain Injury Phase II Clinical Trial
9/20/2017
-
International Stem Cell Corporation Reports Progress In Phase I Clinical Trial For Parkinson's Disease
9/7/2017
-
International Stem Cell Corporation Announces Operating Results For The Three And Six-Months Ended June 30, 2017
8/14/2017
-
International Stem Cell Corporation Announces Operating Results For The Quarter Ended March 31, 2017
5/17/2017
-
International Stem Cell Corporation Receives Approval To Start Second Patient Cohort In Clinical Trial For Parkinson’s Disease
5/9/2017
-
International Stem Cell Corporation Completes First Cohort In Parkinson's Disease Clinical Trial
4/25/2017
-
CryoPort To Provide Cold Chain Logistics Support For International Stem Cell Corporation's Phase I Clinical Trial For The Treatment Of Parkinson's Disease
5/23/2016